ClinicalTrials.gg

Myopia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,163 studies for Myopia across more than 10 countries. 227 are recruiting or about to start. 998 of them are mainly about Myopia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Myopia, Degenerative too: 1,207 studies, 238 open.

ClinicalTrials.gov finds 1,407 studies for Myopia. How that becomes 1,163 here

This page counts the studies the registry files under Myopia, and those it files under no condition that list Myopiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 1,407Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −44Filed under a narrower condition, counted on its own pageMyopia, Degenerative 42
  3. −38List Myopia as a condition, but the registry did not file them under itMost often written as “High Myopia” (24), “Pathologic Myopia” (4), and “Refractive Error - Myopia Axial” (2). The registry filed them under other conditions only, most often Cataract (9) and Refractive Errors (5).
  4. −162Match it another way57 name it in the title, 13 in a keyword, and 92 by a synonym or other text the search reads.
  5. 1,163The count on this page70 of them list Myopia in their own words; the registry filed them under no condition.

Status

Completed
693
Recruiting
120
Status unknown
117
Not yet recruiting
93
Active, not recruiting
78
Terminated
26

Phase

Phase 3
55
Phase 4
48
Phase 2
38
Phase 1
26
Early Phase 1
5

Where

United States
342
China
220
Canada
64
United Kingdom
61
Singapore
43
Taiwan
39

Who develops what

Add Myopia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 7 programs from 7 companies, 7 with this as their studies’ main aim; 3 with a live phase 3 study; 3 primary completions in the next 12 months. Compare Jiangsu HengRui Medicine, Laboratoires Thea and Taejoon Pharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AtropineRecent, limited
Evidence
  • NCT06579287 · Sunhawk Vision Biotech, Inc. · Phase 2 · live · comparator · “Atropine” · registered Aug 2024
Laboratorios Sophia S.A de C.V.12% of its industry studiesUS: off-patent, 24 generics marketedEU: Santen Pharmaceutical Co., Ltd. (EMA 2025)11 study
RanibizumabRecent, limited
Evidence
  • NCT06176352 · Hoffmann-La Roche · Phase 3 · comparator · “Ranibizumab” · registered Dec 2023
Novartis52% of its industry studiesUS: Hoffmann-La Roche (FDA 2006) + 3 othersEU: Novartis (EMA 2007) + 9 others11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
CTO0308☆ Track1 live phase-3 study: NCT07790640Taejoon Pharmaceutical Co., Ltd.
AtropineApproved: US · EU 2025☆ Track1 live phase-3 study: NCT07329777idb visioncare sdn bhd
AtropineApproved: US · EU 2025☆ Track1 live phase-3 study: NCT07028827ocus innovation ireland limited

The 3 in phase 3 with the nearest primary completion, of 7 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Apr 2027 est.CTO0308 · Taejoon Pharmaceutical Co., Ltd. · Phase 3 main aimNCT07790640 Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia — primary endpoint: Change in Spherical Equivalent (SE) · 351 enrolled
  • Sep 2027 est.Atropine · idb visioncare sdn bhd · Phase 3 main aimNCT07329777 Atropine in the Treatment of Myopia Study in Malaysia — primary endpoint: To demonstrate the superiority of eye drop formulation (Atropine Sulphate 0.025% w/v Eye Drops) against placebo determined by Spherical equivalent · 144 enrolled
  • Nov 2027 est.T10430 · Laboratoires Thea · Phase 2 main aimNCT07522242 Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression — primary endpoint: Measure of the occurrence of treatment-emergent adverse events (TEAEs). · 200 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Myopia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimuscarinics 15 open · Angiogenesis inhibitors 4

Coming up

97studies finish main data collection within a year7 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 120 Myopia studies recruiting now, 19 (16%) set no upper age limit and 100 (83%) stop at 75 or younger. 84 (70%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 52 (43%) take healthy volunteers.

Recruiting studies that take each age, of 120
AgeWomenMen
1071 (59%)71 (59%)
1847 (39%)47 (39%)
3042 (35%)42 (35%)
4042 (35%)42 (35%)
5031 (26%)31 (26%)
6520 (17%)20 (17%)
7520 (17%)20 (17%)
8520 (17%)20 (17%)

Across all 1,163 studies, recruiting or not: 65% stop at 75 or younger and 62% at 65; 47% take children; <1% are for women only and 0% for men only; 44% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myopia studies take

Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 326 mo11–57 · 25 studies——
Phase 423 mo8–29 · 18 studies——
Interventional, no phase14 mo3–34 · 434 studies6 mo2–24 · 234 studies26 mo11–44 · 200 studies
Observational24 mo10–59 · 96 studies—26 mo11–90 · 87 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,163. Browse all 1,163 → or search them.